ProThera Biologics
ProThera Biologics is dedicated to developing innovative therapies and diagnostic tools based on Inter-alpha Inhibitor Proteins (IAIP) to treat severe inflammatory diseases, including sepsis, pneumonia, stroke, and neonatal brain injury. The company's mission is to restore immune regulation and control dysregulated inflammation, aiming to improve patient outcomes and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
ProThera Biologics
349 Eddy Street, Providence, RI 02903
Patents
Methods for treating pulmonary disease using inter-alpha inhibitor proteins
US-12285471-B2
View DetailsPreparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US-RE47972-E1
View Details
Methods for treating pulmonary disease using inter-alpha inhibitor proteins
US-12285471-B2
View DetailsPreparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US-RE47972-E1
View DetailsProducts
Plasma-derived inter-alpha inhibitor protein therapeutic (development-stage)
A development-stage plasma protein replacement therapy intended to restore endogenous anti-inflammatory protein levels and modulate multiple inflammatory pathways in severe inflammatory diseases.
IAIP rapid bedside diagnostic (development-stage)
A handheld rapid test to measure circulating levels of an anti-inflammatory plasma protein to predict progression to severe inflammatory outcomes and guide treatment decisions at the bedside.
Plasma-derived inter-alpha inhibitor protein therapeutic (development-stage)
A development-stage plasma protein replacement therapy intended to restore endogenous anti-inflammatory protein levels and modulate multiple inflammatory pathways in severe inflammatory diseases.
IAIP rapid bedside diagnostic (development-stage)
A handheld rapid test to measure circulating levels of an anti-inflammatory plasma protein to predict progression to severe inflammatory outcomes and guide treatment decisions at the bedside.
Services
Collaborative preclinical testing and mechanistic evaluation of plasma protein therapeutics in animal models of sepsis, neonatal brain injury, stroke and toxin-mediated injury.
Development and validation of a rapid bedside test to measure blood levels of a plasma protein biomarker for early prognosis and monitoring of severe inflammatory conditions.
Collaborative IND-enabling work and development partnerships with organizations possessing plasma-derived therapy R&D and manufacturing capabilities to advance clinical development and commercialization.
Collaborative preclinical testing and mechanistic evaluation of plasma protein therapeutics in animal models of sepsis, neonatal brain injury, stroke and toxin-mediated injury.
Development and validation of a rapid bedside test to measure blood levels of a plasma protein biomarker for early prognosis and monitoring of severe inflammatory conditions.
Collaborative IND-enabling work and development partnerships with organizations possessing plasma-derived therapy R&D and manufacturing capabilities to advance clinical development and commercialization.
Expertise Areas
- Plasma-derived protein therapeutic development
- Biomarker discovery and validation
- Point-of-care diagnostic development
- Preclinical disease modeling (sepsis, neonatal brain injury, stroke)
Key Technologies
- Affinity chromatography / affinity-based bioseparation
- Monolithic chromatography for protein purification
- High-specificity immunoassays for protein biomarkers
- Handheld/point-of-care rapid diagnostic devices